Difference between revisions of "Lobaplatin (D-19466)"
Jump to navigation
Jump to search
m Tag: visualeditor |
m |
||
| Line 7: | Line 7: | ||
==Clinical trials== | ==Clinical trials== | ||
| + | <br> | ||
==Also known as== | ==Also known as== | ||
Revision as of 13:20, 17 August 2017
General information
Class/mechanism: Third-generation platinum compound with DNA alkylating activity, producing interstrand DNA crosslinks, which result in apoptosis.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Clinical trials
Also known as
1,2-diammino-methy lcyclobutane-platinum (II) lactate, D-19466